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Abstract
Background Current research into the mechanisms of organ
atrophy associated with cancer cachexia have centred on the
loss of skeletal muscle, as it is one of the most profound
physical changes of the disease. However, many patients with
cancer cachexia also experience significant atrophy of the
heart. The mechanisms causing cardiac tissue wastage in
cancer cachexia are largely unknown. However, it is believed
to involve a number of molecular interactions between the
tumour and host. Increased levels of oxidative stress have
been found in cancer cachectic skeletal muscle and has been
linked to the activation of the ubiquitin proteosome system
(UPS). The aim of the current study was to examine the role of
oxidative stress and the UPS in the hearts of mice with cancer
cachexia.
Methods Oxidative damage to DNA (8-OH-2dG), mRNA
levels of the ROS-producing enzymes NADPH oxidase
(NOX), and xanthine oxidase (XDH), the antioxidant enzyme
superoxide dismutase (SOD) and key components of the UPS
was measured in the heart of mice with cancer cachexia.
Protein expression levels of NOX enzyme subunits and
SOD enzyme activity was also measured in the same heart
samples.
Results 8-OH-2dG levels were 1.5-fold higher in the heart of
mice with cancer cachexia, and this was associated with a 1.7-
fold lower level of NOX2 mRNA and twofold higher XDH
mRNA in the same hearts. Cancer cachexia was also associ-
ated with a 1.5-fold lower level of SOD activity in the heart.
Accompanying these pro- and antioxidant differences was a
significantly higher level of mRNA for the key UPS elements
MURF-1 (4.3=fold) and MAFbx (3.8-fold) in the hearts of
mice with cancer cachexia.
Conclusions The current study demonstrated that cardiac at-
rophy of cachectic mice is associated with oxidative damage
to DNA in the myocardium. The higher levels of XDHmRNA
in cachectic hearts suggest that xanthine oxidase may have an
important role to play in producing oxidative stress. It appears
that the combination of higher XDH expression and lower
SOD enzyme activity are key contributors to oxidative stress
and cardiac tissue damage in cancer-induced cardiac atrophy.
Oxidative stress in the myocardium as with skeletal muscle
may also induce increased expression of the E3 ligases
MURF-1 and MAFbx as seen in this study.
Keywords Cancer cachexia . Oxidative stress . Xanthine
oxidase . NADPH oxidase . Superoxide dismutase .
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1 Introduction
Current research into the mechanisms of organ atrophy asso-
ciated with cancer cachexia (CC) is centred on the loss of
skeletal muscle mass as it is one of the most profound physical
changes of the disease. However, studies have also established
that CC causes significant atrophy of the heart muscle in
animal models [1–3]. Decreases in heart weight by as much
as 60 % have been reported in a rat model of CC [3]. Clinical
research does not currently exist examining the pathologic
consequence of cardiac atrophy in cancer cachexia.
However, Tian et al. used echocardiography to analyse the
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function of cachectic hearts in a mouse model of CC [4]. The
study found that, 14 days after the inoculation with tumour
cells, the hearts of cancer cachectic mice had reduced heart
rate and fractional shortening.
The mechanisms causing cardiac tissue wastage are largely
unknown. However, it is believed to involve a number of
molecular interactions between the tumour and host.
Elevated cytokines in response to tumour presence and
tumour-derived factors such as proteolysis inducing factor
(PIF) and lipid mobilising factor together produce tissue
wasting [5–7]. Host factors such as cytokines including IL-
1, IL-6, TNF-α, INF-γ and PIF derived from the tumour have
been shown to create a state of oxidative stress and net protein
catabolism in skeletal muscle [8]. Similarly increased oxida-
tive stress has been shown to be present in the cachectic heart
[9], but how this is linked to the activation of protein break-
down pathways is currently unknown.
A key catabolic pathway known to contribute to both
skeletal and cardiac muscle atrophy is the ubiquitin
proteosome system (UPS). The UPS is the principle mecha-
nism by which muscle proteins are degraded. The UPS has
been found to be upregulated in both experimental models and
patients with CC [10, 11]. Enzymes which allow ubiquitin to
tag proteins for destruction are termed E3 ligases. Currently,
only three of the discovered several hundred E3 ligases have
been found to be important in the process of muscle atrophy.
These are termed E3 alpha, muscle-specific F-box (MAFbx),
and muscle specific ring finger 1 (MURF-1) [12]. Examining
a model of congestive heart failure, Adams et al. found a
positive correlation between TNF-α and the E3 ligases
MAFbx and MURF-1 [13]. Furthermore, the study found that
TNF-α was able to bring about troponin I ubiquitinylation
leading to impaired contractility of the heart.
Oxidative stress in a CC patient population may be an
important link between the loss of tissue and initiation of
key catabolic pathways [14]. A study by Kaynar et al. found
that patients with either non-small cell or small cell lung
cancer have elevated levels of xanthine oxidase (XO) activity
compared with controls [15]. In the heart, XO is an important
enzyme capable of catalyzing the oxidation of hypoxanthine
and xanthine to uric acid whilst reducing O2 to O2
− and
hydrogen peroxide (H2O2). Traditionally, increases in XO in
the failing heart are associated with ventricular remodelling,
fibrosis, and hypertrophy [16]. The contribution of XO in
cancer-induced cardiac atrophy has not been investigated,
despite the enzyme being implicated in myocardial
remodelling and dysfunction [17, 18]. In terms of atrophy of
the myocardium, like that of skeletal muscle, cardiomyocyte
size is dependent on the relative rates of protein synthesis and
degradation [19]. Increased levels of oxidative stress have
been found in cancer cachectic skeletal muscle and has been
linked to the activation of the UPS [20]. However, no such
studies have examined the role of oxidative stress in the cancer
cachectic heart. The current study aimed to test the hypothesis
that increased levels of oxidative stress in the heart muscle of
mice with cancer cachexia is associatedwith and up regulation
of the UPS.
2 Materials and methods
2.1 Animals
All experimental procedures were carried out with approval
from the Victoria University animal ethics committee
(AEETH 07/05). Six-week-old BALB/c nu/nu nude mice
purchased from the Animal Resource Centre, Western
Australia, and were acclimatised for 1 week prior to injection
of the cancer cell lines. Animals were maintained under con-
trolled conditions of a 12-h light/dark cycle at 21 °C. Food and
water were provided ad libitum. Food and water were weighed
before and after the experimental period to ensure weight loss
in the CC group was not due to a decrease in caloric intake.
Animals were randomised into three weight-matched groups
consisting of a no cancer (control, n =8), cancer without
cachexia control (cancer, n =12) and cancer with cachexia
(cachexia, n =16).
2.2 Tumour model
Cancer and cancer cachexia were induced as previously de-
scribed [25]. In brief, the murine adeno-carcinoma cell lines
13 (MAC13) and 16 (MAC16) were cultured in RPMI with
10 % FBS and 0.5 % penicillin/streptomycin (Invitrogen).
Mice inoculated with the MAC13 cell line develop a malig-
nant tumour without cachexia and are used as a cancer control
(cancer). The MAC16 cell line produces a both solid tumour
and cachexia (cachexia). Cells were kept in a humidified
incubator at 37 °C in 10 % CO2. Cells were grown to 80 %
confluence and removed from cell culture flasks via
trypsinisation. These cells were centrifuged at 500×g for
5 min at 4 °C and isolated from the growth media. Cells were
then resuspended in sterile PBS pre-incubated to 37 °C and
drawn up into a sterile syringe with a 25-gauge needle for
subsequent injection into mice. Mouse body weights were
recorded daily, and tumour size was measured using calipers.
Animals were euthanised before weight loss in the cachexia
group reached 25 % of their initial weight or before tumour
growth exceeded 1,000 mm3; this occurred at 30±3 days.
Tissues were harvested and immediately placed in liquid
nitrogen before storing in an −80 °C freezer for later analysis.
In the case of the heart, it was removed intact, blotted to
remove any blood, and weighed. The atria and any remaining
portions of the great vessels were then removed prior to the
ventricles being frozen.
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2.3 SOD enzyme activity
Heart tissues were washed in heparinised PBS, and 15 mg of
tissue was used for enzyme activity assays. Heart tissue was
homogenized in 5 ml of 20 mM HEPES buffer (pH 7.2)
containing 1 mM EGTA, 210 mM mannitol and 70 mM
sucrose per gram of tissue. Samples were standardised so that
10 ul of sample with 10 mg of protein was added to each well
on the 96-well assay plate. The assay kit detecting total SOD
activity was undertaken as per the manufacturer’s instructions
(Cayman Chemical). The amount of activity was calculated
and standardised for protein using the Bradford method (Bio-
Rad).
2.4 DNA oxidation assay
An ELISA kit was used to measure the DNA oxidation
byproduct 8-hydroxy-2-deoxy guanosine (StressMarq
Biosciences). DNAwas extracted from 15 mg of tissue using
a DNA isolation kit (Promega). Each sample was then diluted
so that 50 ug of DNA was used in the 8-hydroxy-2-deoxy
guanosine assay. The competitive immunoassay involves the
binding of free 8-hydroxy-2-deoxy guanosine to an antibody
coated 96-well plate. The assay and sample concentration of
8-hydroxy-2-deoxy guanosine was carried out as per the man-
ufacturer’s instructions.
2.5 RT-PCR
RNAwas extracted from frozen heart tissue samples using tri-
reagent (Molecular Research Centre). Total RNA concentra-
tion yielded per sample was quantified spectrophotometrically
at 260 nm. All samples were reverse-transcribed to cDNA
using reverse transcription kit (Marligen). cDNAwas stored at
−20 °C until further analysis. All primer sequences were
designed using Primer 3 (primer sequences shown in
Table 1). Real-time PCR was performed using a IQ 5 PCR
detection system (Bio Rad). A supermix (Bio Rad) was pre-
pared containing 10 ng of sample cDNA, forward and reverse
primers diluted to a final concentration of 300 nM, in a total
volume of 25 ul. Quantification of mRNA expression was
achieved by running samples in duplicate and over a period of
40 cycles. Flourescence data were tabulated and mRNA levels
quantified using threshold cycle values. 18S was used as a
housekeeping gene to compensate for variations in input RNA
amounts by normalizing values to this gene.
2.6 Protein quantification
Heart tissue was homogenized in 20 mM HEPES buffer. The
homogenate was centrifuged, and the supernatant was collect-
ed and placed on ice. Protein content was assayed using the
BCA Protein Assay Kit (Bio Rad). Fifty micrograms of total
cellular protein was then loaded on 12 % polyacrylamide gels
(NuSep) and separated by standard SDS-PAGE. Gels were
then transferred to polyvinylidine fluoride membranes (Bio
Rad). Blots were blocked with Tris-buffered saline including
0.1 % Tween 20 and 5 % nonfat dried milk. Primary antibody
(Santa-Cruz) against p47phox, NOX2, and GAPDH at a dilu-
tion of 1 in 2,000 was added to the membrane overnight at
4 °C. Secondary donkey–antigoat antibodies (Santa-Cruz)
conjugated to HRP at a 1 in 10,000 dilution was added to
the membrane for 1 h at room temperature. Antigen–antibody
complexes were analysed by chemiluminescence using the
immune-star HRP detection kit (Bio Rad). Subsequent devel-
opment and detection of the membrane was achieved with the
Chemidoc system (Bio Rad). Protein expression data were
then analysed using the Quantity One software (Bio Rad).
2.7 Statistical analysis
The reported values are expressed as mean±SEM. Data were
analyzed using two-way ANOVA, with a Tukey’s test post
hoc analysis performed to determine differences between
Table 1 PCR primer sequences
Gene Forward primer (5′-3′) Reverse primer (5′-3′)
18 s GTAACCCGTTGAACCCCATT ATCCAATCGGTAGTAGCG
MURF-1 AGGAGCAAGTAGGCACCTCA GTCCATGTCTGGAGGTCGTT
MAFbx AAGATCAAACGCTTGCGAAT GAACATCATGCAGAGGCTGA
NOX1 TGGTCATGCAGCATTAAACTTTG CATTGTCCCACATTGGTCTCC
NOX2 TTGGGTCAGCACTGGCTCTG TGGCGGTGTGCAGTGCTATC
NOX4 TGTTGGGCCTAGGATTGTGTT AAAAGGATGAGGCTGCAGTTG
p67phox CTGGCTGAGGCCATCAGACT AGGCCACTGCAAGAGTGCTTG
p40 phox GCCGCTATCGCCAGTTCTAC GCAGGCTCAGGAGGTTCTTC
CuZn SOD TGAACCAGTTGTGTTGTCAG TCCATCACTGGTCACTAGCC
Mn SOD TGGCTTGGCTTCAATAAGGA AAGGTAGTAAGCGTGCTCCCACAC
XDH ATCTGGAGACCCACTGCACC TGTGCTCACGAAGAGCTCCAT
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groups where appropriate. Significance was set at a P value
equal to or <0.05
3 Results
The animals in this study were randomised to one of three
groups being a no-tumour control, cancer or cancer cachexia.
Animals in the cachexia group displayed all of the hallmarks
of cancer cachexia including the loss of body weight (P=
0.003), skeletal (P=0.003) and cardiac (P=0.002) muscle
with no significant differences in food and water intake be-
tween the groups (Table 2). An analysis was then carried out
to ascertain whether key oxidative and proteolytic pathways
were upregulated in cardiac tissue.
Oxidative damage in the heart muscle was assessed by
measuring 8-hydroxy-2-deoxyguanosine (8-OH-2dG), a bio-
marker of DNA oxidation (Fig. 1). The hearts of cachectic
mice displayed a significant 1.5-fold higher 8-OH-2dG (71±
26 pg/ml) concentration compared with control (45±18 pg/
ml, P=0.02) and cancer (43±24 pg/ml, P=0.015) groups.
Further studies were then carried out to assess which pathways
may be contributing to the oxidative damage in the cancer
cachectic hearts.
To investigate the potential source of oxidative stress con-
tributing to the oxidative DNA damage found in the cachectic
hearts, we investigated the ROS producing enzymes, NADPH
oxidase and XO. RT-PCR was performed on the key regula-
tory subunits (p40 phox and p67 phox) and the catalytic core
units (NOX1, NOX2 and NOX4) of NADPH oxidase. There
were no changes in the key regulatory or catalytic core units of
NADPH oxidase in the heart muscle samples except for
NOX2 (Table 3). The current experiment found a significant
1.7-fold lower level of gene expression for NOX2 in cachectic
hearts (P=0.03) compared with the cancer group (Table 3). To
assess the possibility of posttranslational modification to the
NADPH oxidase protein components, a protein expression
analysis was undertaken on p47phox and NOX2. There was
no significant difference in either p47phox and NOX2 protein
abundance in the cancer cachectic hearts compared with both
the control and cancer groups (Table 3).
Subsequently, the XDH enzymatic pathway known to pro-
duce ROS was investigated. The RT-PCR results showed a
significant twofold higher level of XDH mRNA (P=0.04) in
the heart of cachexia mice in comparison to control and cancer
groups (Table 3). Other possible contributors to the state of
Table 2 Body weight, organ weights, food and water intake
Control (n =8) Cancer (n =12) Cachexia (n =16)
Body weight (g) 21.7±0.4 22.3±0.3 17.6±0.5*#
Heart weight (mg) 121.0±0.01 112.6±0.01 92.0±0.01*#
Quadriceps (mg) 122.9±2.6 117.0±4.2 90.1±2.1*#
Food (g) 3.84±0.55 3.58±0.34 3.64±0.47
Water (ml) 3.92±0.13 3.61±0.13 3.80±0.21
Values are expressed as mean±SEM
*P<0.05, significantly different from control group
#P<0.05, significantly different from cancer group
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Fig. 1 DNA oxidation by-product 8-hydroxy-2-deoxyguanosine con-
centration in control, cancer and cachexia. Values are expressed as
mean±SEM. Significantly different from control group (P<0.02). #Sig-
nificantly different from cancer group (P<0.05)
Table 3 Gene and protein expression data
Gene Control (n=8) Cancer (n =12) Cachexia (n =16)
MURF-1 2.5±1.0 1.8±0.5 4.0±1.0#
MAFbx 1.4±0.8 1.6±0.9 6.3±2.0#*
NOX1 482±117 440±50 343±52
NOX2 176±48 177±32 99±21#
NOX4 16±7 8±3 9±2
P67 73.1±12.3 87.4±15.2 89.6±9.3
P40 865±125 452±23 263±49
CuZn SOD 490±106 587±168 458±115
Mn SOD 412±73 431±73 666±215
XDH 453±69 469±69 1421±69*#
Protein expression
p47phox 1.6±0.5 2.0±0.4 2.2±0.6
NOX2 0.9±0.1 0.6±0.1 1.0±0.3
Gene expression values are expressed as arbitrary units, mean±SEM.
Protein expression values are expressed as, band intensity (square
millimetres) adjusted for GAPDH, mean±SEM
* P <0.05, significantly different from control group
#P<0.05, significantly different from cancer group
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oxidative stress observed in the cachectic hearts may have
been the suppression of the antioxidant enzyme, superoxide
dismutase (SOD). Mitochondrial and cytoplasmic SOD
displayed no change in mRNA levels (Table 3). However,
further investigation of total SOD enzyme activity showed a
significant 1.5-fold lower activity in mice with cachexia com-
pared with control (P=0.02) and cancer (P=0.001, Fig. 2).
Accompanying a state of oxidative stress in cancer cachec-
tic hearts were higher levels of expression of the major muscle
proteolytic pathway, the UPS. MURF-1 and MAFbx mRNA
expression was significantly higher, 4.3-fold (P=0.04) and
3.8-fold (P=0.04), respectively, in the hearts of the cachexia
mice compared with the cancer group (Table 3).
4 Discussion
The cardiac atrophy secondary to CC observed in this study is
associated with a pro-oxidative shift and consequential oxida-
tive myocardial tissue damage. Furthermore, upregulation of
the key ubiquitin ligases in cachectic hearts suggests induction
of the UPS may be in response to oxidative stress and subse-
quent protein damage.
The current study demonstrated the importance of cardiac
atrophy as a hallmark of the disease with an average 20 %
decrease in heart muscle weight compared with controls.
The consequence of such cardiac atrophy was demonstrated
by Tian et al. who used echocardiography to analyse the
function of cachectic hearts in a mouse model of cancer ca-
chexia [4]. Their study found that, 14 days after the inoculation
with tumour cells, the hearts of cancer cachectic mice had
reduced heart rate and fractional shortening [4]. To date, the
mechanisms influencing cardiac tissue wasting in a state of CC
are largely unknown. However, previous studies have shown
that patients and animals with CC all show degrees of oxidative
stress [21, 22]. To elucidate whether a state of oxidative stress
exists in the heart of mice afflicted with CC, the current study
measured levels of 8-Oh-2dG and found a significantly higher
levels in the cachexia group hearts. The higher 8-Oh-2dG
suggests that the activation of pro-oxidant pathways in
atrophied hearts of cachectic mice. Importantly, both the release
of cytokines such as TNF-alpha and tumour-derived factors
such as PIF have been shown to have pro-oxidant effects [20,
21]. Gomes-Marcondes and Tisdale used myotubes in cell
culture exposed to FeSO4 and H2O2 which showed that key
components of the ubiquitin proteasome system were
upregulated by oxidative stress [20]. NOX2 mRNA expression
was lower in cachexia hearts compared with the control group,
while the Western blot data were unchanged. The results sug-
gest a decreased role for NADPH oxidase in contributing to
cellular oxidative stress in cachectic hearts. The results are also
in keeping with a previous study by Sullivan-Gunn showing a
decrease in NOX2 levels in skeletal muscles of cancer cachec-
tic mice [23]. The animals in this study were allowed to lose up
to 25 % of their initial body weight, thus constituting late-stage
cachexia. Considering that NADPH oxidase enzyme activity
has been shown to degrade cultured myotubes in vitro [23], a
time course study would be beneficial in understanding wheth-
er the current results are specific to cardiac atrophy in late
cachexia. Another key pathway of ROS formation in the myo-
cardium is XDH that was measured using RT-PCR. The results
showed a twofold higher level of XDH in the cachexia group
hearts. The activation of XDH has been implicated in a number
of disease states involving the myocardium such as heart failure
and myocardial dysfunction [16, 17]. A study by Ekelund et al.
highlighted the importance of XO in cardiac disease by show-
ing that inhibition of the enzyme by allopurinol is capable of
increasing left ventricular function and decreasing myocardial
oxygen consumption in a dog model of heart failure [24].
In evaluating the potential contribution of antioxidant sys-
tems in the cachectic heart, SOD was analysed both at a gene
and enzyme activity level. The SOD enzyme is a key endog-
enous antioxidant in the myocardium for the elimination of
superoxide and has been implicated in the pathogenesis of CC
[25]. Interestingly, while the cytosolic andmitochondrial SOD
mRNA levels were unchanged in cachectic hearts, total SOD
enzyme activity was significantly lower compared with con-
trols. This suggests that the SOD enzyme is not compensating
for increased levels of ROS. Thus, the concurrent higher
levels of XDH and lower SOD activity may significantly
contribute to a disruption in the balance between pro-oxidant
and antioxidant mechanisms, leading to a state of oxidative
stress as evidenced by greater oxidative damage to DNA (8-
SO
D
 a
ct
iv
ity
 (U
nit
/m
g p
ro
tei
n)
Control Cancer Cachexia
*
Fig. 2 Total SOD activity in control, cancer and cachexia. Values are
expressed as mean±SEM. *Significantly different from control group (P
<0.05). #Significantly different from cancer group (P<0.05)
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Oh-2dG) in the cachectic heart. With respect to how oxidative
stress may contribute to cardiac atrophy in CC, it is currently
unknown; however, evidence suggests induction of the UPS
may be an important link between oxidative stress and atrophy
in cachectic muscle [20]. Otsuka et al. found that in patients’
hearts undergoing dilated cardiomyopathy, oxidative stress
and the UPS activation are colocalised [26]. Increases in levels
of XO and altered SOD enzyme function in the myocardium
are traditionally linked to cardiac fibrosis and cardiomypathies
[16, 27]. However, the current study shows an association
between oxidative stress and cardiac atrophy, suggesting an
alternative pathologic role for oxidants in the myocardium. In
elucidating the mechanisms by which ROS contributes to the
loss of lean body mass, Gomes-Marcondes and Tisdale
attempted to replicate the oxidative stress seen in cancer
cachexia by using murine myotubes in cell culture [20]. The
myotube cells were exposed to H2O2 which induced oxidative
stress. Their results showed that the induction of oxidative
stress caused an increase in the expression of important UPS
elements including the 20S proteasome and the E214k conju-
gating enzyme [20].
The UPS E3 ligasesMURF-1 andMAFbx are expressed in
cardiomyocytes and are an important component of cardiac
protein turnover [28]. Increased mRNA expression of these
ligases is linked to the degradation of cardiac troponin I, α-
actin-2 and MyoD leading to impaired contractility [13, 29].
This study shows that both MURF-1 and MAFbx are
upregulated at the mRNA level (Table 3) which is in keeping
with results seen in studies analysing cachectic heart muscle
tissue [30]. Interestingly, Cosper and Leinwand using CD2F1
hybrid mouse model of CC did not see any change in the UPS
but found an upregulation in autophagy-related protein deg-
radation [2]. However, the study by Tian et al. using a mouse
model of CC similarly to this study found that mRNA of UPS
E3 enzymes to be increased in cachectic hearts [30].
Furthermore, Tian and colleagues found that there was in-
creased protein ubiquitinylation in the hearts of cancer ca-
chexia mice compared with controls suggesting that indeed
the UPS has an important role to play in cardiac atrophy
secondary to CC [30]. A limitation of the current study is
the changes in MURF-1 and MAFbx that are at the mRNA
level and so correlative in nature. Future investigations would
include the evaluation of UPS activation, the state of activa-
tion of other proteolytic systems and the phosphorylation
levels of Akt and Foxo proteins upstream of ubiquitin ligase
activation.
5 Conclusion
The current study used a mouse model of CC producing
significant body weight loss and a reduction in heart mass
by 20 %. The experimental data demonstrated that cardiac
atrophy of cachectic mice is related to a state of oxidative
DNA damage in the myocardium. Levels of XDH mRNA
were higher in CC hearts, suggesting that XO may have an
important role to play in producing oxidative stress. Most
evidently, it appears that the combination of higher XDH
expression and lower SOD enzyme activity are key contribu-
tors to oxidative stress and cardiac tissue damage in cancer-
induced cardiac atrophy. Oxidative stress in themyocardium as
with skeletal muscle may also induce increased expression of
the E3 ligases MURF-1 and MAFbx as seen in higher mRNA
levels of both in this study. Further research is needed in a time-
dependent manner to ascertain whether these changes are seen
in early cachexia and are indeed initiating mechanisms.
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